Cargando…
Humoral response to SARS-CoV-2 mRNA vaccine on in ABO blood type incompatible kidney transplant recipients treated with low-dose rituximab
We aimed to evaluate the humoral response after the second and third doses of SARS-CoV-2 mRNA vaccine in ABO blood type incompatible kidney transplant (KT) recipients treated with rituximab. This retrospective study conducted between June 2021 and June 2022 included 131 KT recipients and 154 nontran...
Autores principales: | Hamaya, Tomoko, Hatakeyama, Shingo, Yoneyama, Tohru, Tobisawa, Yuki, Kodama, Hirotake, Fujita, Takeshi, Murakami, Reiichi, Mori, Kazuyuki, Okamoto, Teppei, Yamamoto, Hayato, Yoneyama, Takahiro, Hashimoto, Yasuhiro, Saitoh, Hisao, Narumi, Shunji, Tomita, Hirofumi, Ohyama, Chikara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497504/ https://www.ncbi.nlm.nih.gov/pubmed/37699969 http://dx.doi.org/10.1038/s41598-023-42406-5 |
Ejemplares similares
-
Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients
por: Hamaya, Tomoko, et al.
Publicado: (2022) -
Narrative review of urinary glycan biomarkers in prostate cancer
por: Hatakeyama, Shingo, et al.
Publicado: (2021) -
N‐glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas
por: Kodama, Hirotake, et al.
Publicado: (2021) -
Recent progress and perspectives on prostate cancer biomarkers
por: Hatakeyama, Shingo, et al.
Publicado: (2016) -
Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
por: Hamano, Itsuto, et al.
Publicado: (2020)